Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations.

Covy JP, Yuan W, Waxman EA, Hurtig HI, Van Deerlin VM, Giasson BI.

Mov Disord. 2009 Jan 15;24(1):32-9. doi: 10.1002/mds.22096.

2.

Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.

Gaig C, Ezquerra M, Martí MJ, Valldeoriola F, Muñoz E, Lladó A, Rey MJ, Cardozo A, Molinuevo JL, Tolosa E.

J Neurol Sci. 2008 Jul 15;270(1-2):94-8. doi: 10.1016/j.jns.2008.02.010. Epub 2008 Mar 19.

PMID:
18353371
3.

α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.

Covy JP, Giasson BI.

Neurotoxicology. 2011 Oct;32(5):622-9. doi: 10.1016/j.neuro.2011.01.003. Epub 2011 Jan 14. Review.

4.

Biochemical and pathological characterization of Lrrk2.

Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM.

Ann Neurol. 2006 Feb;59(2):315-22.

PMID:
16437584
5.

Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease.

Tan EK, Skipper L, Chua E, Wong MC, Pavanni R, Bonnard C, Kolatkar P, Liu JJ.

Mov Disord. 2006 Jul;21(7):997-1001.

PMID:
16602113
6.

Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain.

Gao L, Gómez-Garre P, Díaz-Corrales FJ, Carrillo F, Carballo M, Palomino A, Díaz-Martín J, Mejías R, Vime PJ, López-Barneo J, Mir P.

Eur J Neurol. 2009 Aug;16(8):957-60. doi: 10.1111/j.1468-1331.2009.02620.x. Epub 2009 Mar 31.

PMID:
19473361
7.

Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data.

Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW.

Brain. 2005 Dec;128(Pt 12):2786-96. Epub 2005 Nov 4.

PMID:
16272164
8.

Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants.

Xiromerisiou G, Hadjigeorgiou GM, Gourbali V, Johnson J, Papakonstantinou I, Papadimitriou A, Singleton AB.

Eur J Neurol. 2007 Jan;14(1):7-11.

PMID:
17222106
9.

G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Gaig C, Martí MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E.

J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8. Epub 2007 Jan 8.

10.

A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease.

Haubenberger D, Bonelli S, Hotzy C, Leitner P, Lichtner P, Samal D, Katzenschlager R, Djamshidian A, Brücke T, Steffelbauer M, Bancher C, Grossmann J, Ransmayr G, Strom TM, Meitinger T, Gasser T, Auff E, Zimprich A.

Mov Disord. 2007 Aug 15;22(11):1640-3.

PMID:
17523199
11.

Parkinsonism, Lrrk2 G2019S, and tau neuropathology.

Rajput A, Dickson DW, Robinson CA, Ross OA, Dächsel JC, Lincoln SJ, Cobb SA, Rajput ML, Farrer MJ.

Neurology. 2006 Oct 24;67(8):1506-8.

PMID:
17060589
12.

[Advance of the study on LRRK2 gene in Parkinson's disease].

Zhang Y, Chen S.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Dec;25(6):657-9. Review. Chinese.

PMID:
19065525
13.

LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.

Gaig C, Ezquerra M, Marti MJ, Muñoz E, Valldeoriola F, Tolosa E.

Arch Neurol. 2006 Mar;63(3):377-82.

PMID:
16533964
14.

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM.

Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7. Epub 2005 Nov 3.

15.

Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.

Floris G, Cannas A, Solla P, Murru MR, Tranquilli S, Corongiu D, Rolesu M, Cuccu S, Sardu C, Marrosu F, Marrosu MG.

Parkinsonism Relat Disord. 2009 May;15(4):277-80. doi: 10.1016/j.parkreldis.2008.06.009. Epub 2008 Sep 20.

PMID:
18805725
16.

Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.

Giordana MT, D'Agostino C, Albani G, Mauro A, Di Fonzo A, Antonini A, Bonifati V.

Mov Disord. 2007 Jan 15;22(2):275-8.

PMID:
17149743
17.

LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.

Lesage S, Janin S, Lohmann E, Leutenegger AL, Leclere L, Viallet F, Pollak P, Durif F, Thobois S, Layet V, Vidailhet M, Agid Y, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group, Bonnet AM, Borg M, Broussolle E, Damier P, Destée A, Martinez M, Penet C, Rasco O, Tison F, Tranchan C, Vérin M.

Arch Neurol. 2007 Mar;64(3):425-30.

PMID:
17353388
18.

A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.

Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva GKh, Markova ED, Limborska SA, Ivanova-Smolenskaya IA.

Eur J Neurol. 2007 Apr;14(4):413-7.

PMID:
17388990
19.

Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation.

Johnson J, Paisán-Ruíz C, Lopez G, Crews C, Britton A, Malkani R, Evans EW, McInerney-Leo A, Jain S, Nussbaum RL, Foote KD, Mandel RJ, Crawley A, Reimsnider S, Fernandez HH, Okun MS, Gwinn-Hardy K, Singleton AB.

Neurodegener Dis. 2007;4(5):386-91. Epub 2007 Jul 6.

PMID:
17622782
20.

Clinical genetics of Parkinson's disease and related disorders.

Wider C, Wszolek ZK.

Parkinsonism Relat Disord. 2007;13 Suppl 3:S229-32. doi: 10.1016/S1353-8020(08)70007-5. Review.

PMID:
18267241

Supplemental Content

Support Center